Hospital Ward 3T
The Nuclear Medicine Ward at the Medical University of Vienna offers a broad range of both established and innovative radionuclide therapies. These treatments are targeted, meaning the radioactive drugs primarily bind to specific areas of the affected organ or organ system, delivering their therapeutic effects right where they’re needed and minimizing impact on the rest of the body.
We provide the latest advancements in modern nuclear medicine for your treatment. If you have any questions before your visit or need special assistance during your stay, please don’t hesitate to reach out. We’re here to help!
Our entire team on Ward 3T is dedicated to your health with both commitment and expertise.
For information on inpatient admission, please refer to the following topics:
- Radioiodine Therapy
- Peptide Receptor Radionuclide Therapy (PRRT)
We offer the following therapies:
- Radioiodine therapy for hyperthyroidism
- Radioiodine therapy for thyroid cancer
- Treatment for metastatic prostate cancer with 177Lu-PSMAI&T
- Treatment for bone metastases with Ra-223 (Xofigo)
- Treatment for neuroendocrine tumors with 177Lu-DOTATATE
- Selective internal radiation therapy for liver tumors (SIRT)
- Radiosynoviorthesis